Arcus Biosciences, Inc. (NYSE:RCUS) Given Consensus Rating of “Buy” by Brokerages

Shares of Arcus Biosciences, Inc. (NYSE:RCUS) have received a consensus rating of “Buy” from the nine research firms that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $34.00.

A number of equities research analysts have weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a research report on Thursday, November 7th. Evercore ISI upgraded shares of Arcus Biosciences to a “strong-buy” rating in a report on Friday, August 9th. Barclays upped their price target on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Finally, HC Wainwright reissued a “neutral” rating and set a $20.00 target price on shares of Arcus Biosciences in a research note on Wednesday, November 6th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd purchased a new stake in Arcus Biosciences during the 3rd quarter worth about $47,000. Innealta Capital LLC purchased a new stake in shares of Arcus Biosciences during the second quarter worth approximately $66,000. Point72 DIFC Ltd acquired a new stake in Arcus Biosciences in the second quarter valued at approximately $83,000. Quest Partners LLC lifted its stake in Arcus Biosciences by 40,904.3% in the third quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock worth $144,000 after acquiring an additional 9,408 shares during the last quarter. Finally, Diversified Trust Co grew its holdings in Arcus Biosciences by 12.1% during the 2nd quarter. Diversified Trust Co now owns 13,545 shares of the company’s stock worth $206,000 after acquiring an additional 1,467 shares in the last quarter. 92.89% of the stock is currently owned by hedge funds and other institutional investors.

Arcus Biosciences Trading Down 2.3 %

Shares of Arcus Biosciences stock opened at $15.44 on Monday. The stock has a 50 day moving average of $16.24 and a 200 day moving average of $16.03. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -4.90 and a beta of 0.89. Arcus Biosciences has a fifty-two week low of $13.52 and a fifty-two week high of $20.31.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.06. The business had revenue of $48.00 million during the quarter, compared to analysts’ expectations of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company’s revenue was up 50.0% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.94) EPS. As a group, research analysts predict that Arcus Biosciences will post -3.2 earnings per share for the current year.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.